The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Stopping Ozempic or Wegovy often leads to significant weight regain within 1-1.5 years, reversing gains in blood sugar, pressure, and cholesterol. Experts explain the science behind this, from metabolic adaptation to surging appetite. Understand how to approach GLP-1 therapy for long-term success.
Medicare is breaking its long-standing rule against covering weight loss drugs like Wegovy and Zepbound through a new GLP-1 initiative. Starting with a bridge phase in July 2026, eligible beneficiaries could pay just $50 monthly copays—if they act now. This guide explains the changes, requirements, and clinical context for GLP-1 therapy.
Karren Brady, the 56-year-old Apprentice star and baroness, has slammed 'belittling' Ozempic rumors about her slimmer figure. She attributes her transformation to cycling, walking, and healthy eating. Discover the truth behind GLP-1 medications and how to achieve lasting weight loss naturally or with meds.
Many users like the author experience devastating weight regain shortly after stopping Mounjaro, mirroring real-world and trial data. This guide unpacks the physiology, backed by studies, and offers practical steps to sustain your progress. Don't let hard-won losses slip away—arm yourself with knowledge.
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but fears of muscle wasting persist. Clinical evidence reveals these drugs cause modest, proportional lean mass changes while enhancing muscle quality. Discover the science and practical steps to optimize outcomes.
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound now make up over 7% of U.S. prescriptions, fueling weight loss trends but raising safety concerns. From FDA warnings on sharing pens to charges over fake drugs, here's what patients need to know. Discover emerging research and tools to manage your therapy safely.
Roche's experimental obesity drug CT-388 delivered impressive 22.5% average weight loss in a phase 2 trial, surpassing Novo Nordisk's Wegovy and rivaling Eli Lilly's Zepbound. Over half of participants resolved obesity by dropping below a BMI of 30. This positions Roche as a serious contender in the booming GLP-1 market.
A large theft of Mounjaro from a UK distributor underscores the growing black market risks for GLP-1 weight loss drugs. Improperly stored or fake versions can be dangerous—here's how to source tirzepatide safely. This guide covers storage needs, scam red flags, and best practices for metabolic health.
Amanda Bynes recently shared her 28-pound weight loss journey on Ozempic, dropping from 180lbs to 152lbs and feeling inspired. This celebrity story highlights the growing popularity of GLP-1 medications for weight management. Learn the science, evidence, and practical advice behind these powerful tools.
